

EQA round: RFA1/24 - Risk Factors for Atherosclerosis

Deadline: 5.4.2024

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(114) Apolipoprotein AI	[g/L]				11							11	11	100
Sample A												11	11	100
(2) Immunoturbidimetry		1,2	0,089	7,4	11	0	CVP	1,19	0,021	17%	0,987	1,4	11	
Sample B												11	11	100
(2) Immunoturbidimetry		1,61	0,11	6,9	11	0	CVP	1,6	0,028	17%	1,32	1,88	11	
(115) Apolipoprotein B	[g/L]				14							14	11	79
Sample A												14	13	93
(2) Immunoturbidimetry		0,718	0,055	7,6	14	0	CVP	0,703	0,008	14%	0,604	0,802	14	
Sample B												14	12	86
(2) Immunoturbidimetry		1,01	0,08	7,9	14	0	CVP	0,997	0,012	14%	0,857	1,14	14	
(111) Cholesterol	[mmol/L]				39							39	38	97
Sample A												39	39	100
(0) Not specified		3,83	0,11	3	39	0	CVP	3,79	0,015	8%	3,48	4,1	39	
Sample B												39	38	97
(0) Not specified		5,31	0,17	3,3	39	0	CVP	5,25	0,022	8%	4,83	5,67	39	
(113) Cholesterol HDL	[mmol/L]				40							40	40	100
Sample A												40	40	100
(2) Direct determination		1,09	0,042	3,8	40		CVP	1,11	0,007	15%	0,943	1,28	40	
Other		1,09	0,042	3,8	39	0						39		
					1	0						1		
							1x 1							
Sample B												40	40	100
(2) Direct determination		1,42	0,064	4,5	40		CVP	1,42	0,009	15%	1,2	1,64	40	
Other		1,42	0,065	4,6	39	0						39		
					1	0						1		
							1x 1							
(118) Cholesterol LDL (direct determination)	[mmol/L]				36							36	36	100
Sample A												36	36	100
(0) Not specified		2,35	0,15	6,4	36	0	CVP	2,33	0,022	20%	1,86	2,8	36	
Sample B												36	36	100
(0) Not specified		3,27	0,27	8,2	36	0	CVP	3,24	0,04	20%	2,59	3,89	36	
(116) Cholesterol LDL (calculation)	[mmol/L]				11							11	10	91
Sample A												11	11	100
(0) Not specified		2,34	0,13	5,6	11	0	CVP	2,27	0,028	15%	1,92	2,62	11	
Sample B												11	10	91
(0) Not specified		3,23	0,21	6,4	11	0	CVP	3,13	0,04	15%	2,66	3,6	11	
(117) Lipoprotein (a) [g/L]	[g/L]				6							6	6	100
Sample A												6	6	100
(2) Immunoturbidimetry		0,161	0,019	12	6	0	CVP	0,157	0,005	25%	0,117	0,197	6	
Sample B												6	6	100
(2) Immunoturbidimetry		0,278	0,018	6,4	6	0	CVP	0,279	0,008	25%	0,209	0,349	6	
(119) Lipoprotein (a) [nmol/L]	[nmol/L]				5							5	5	100
Sample A												5	5	100
(2) Immunoturbidimetry		23,7	1	4,4	5	0	CVP	24,8	0,85	20%	19,8	29,8	5	
Sample B												5	5	100
(2) Immunoturbidimetry		47,5	2,4	5	5	0	CVP	49,6	1,2	20%	39,6	59,6	5	
(112) Triacylglycerols	[mmol/L]				39							39	39	100
Sample A												39	39	100
(1) Photometric enzyme (GPO-PAP)		0,91	0,04	4,4	39		CVP	0,919	0,006	15%	0,781	1,06	39	
Other		0,912	0,041	4,4	36	0						36		
					3	0						3		
							3x 2							
Sample B												39	39	100
(1) Photometric enzyme (GPO-PAP)		1,6	0,048	3	39		CVP	1,62	0,008	15%	1,37	1,87	39	
Other		1,61	0,048	3	36	0						36		
					3	0						3		
							3x 2							